Katie Couric's Breast Cancer The popular media personality is on a mission to raise awareness around dense breasts Oct 06, 2022
FDA's Power Morcellator Warning Tied to Drop in Distant Leiomyosarcomas Local and regional illness remained unchanged Oct 04, 2022
Combo Therapy Shows Promise in Advanced Thymic Epithelial Tumors "Clinically remarkable outcomes" with PD-L1 inhibitor plus anti-angiogenesis agent Oct 04, 2022
Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomes One in five patients experienced changes in their care plan Oct 04, 2022
SABR for Oligometastatic Cancer Turns in 'Acceptable' Rates of Toxicity Rates of grade 2 or higher toxicities less than those observed in landmark SABR-COMET study Oct 03, 2022
Adding Chemo Not Better for Recurrent Endometrial Cancer Trial suggests radiation therapy alone remains standard of care for pelvic-only recurrences Oct 03, 2022
Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
Durvalumab-CRT Pairing Disappoints in Locally Advanced Cervical Cancer Still, CALLA trial findings "will inform future strategies to improve treatment," researcher says Oct 02, 2022
ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says Oct 01, 2022
'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer Post-hoc data from SOLO3 show diverging results based on prior lines of therapy Sep 30, 2022
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML? Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination "Clinically meaningful" improvement in 2- and 3-year survival Sep 28, 2022
Was I Conned by a 'Grey's Anatomy' Writer? Her alleged duplicity could make things tougher for female patients Sep 27, 2022
Cancer in Kids Tied to Prenatal Exposure to High-Dose Folic Acid and Seizure Meds But no link seen among children of mothers without epilepsy Sep 26, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy Sep 22, 2022
How Does Oncology Deal With Pandemic Burnout? Evidence suggests the pandemic could have long-term consequences Sep 20, 2022
Closing Colorectal Cancer Screening Gaps With FIT Initiative VA hospital meets goal of increasing monthly screenings to address backlog from pandemic Sep 19, 2022
Radiation Oncology Residents Report Deficits in Training During the Pandemic About half worry about job prospects Sep 19, 2022
How a Dedicated Bone Marrow Biopsy Clinic Eased Wait Times VA center in Cleveland got program up and running in about a month Sep 19, 2022
Clinical Decision Tool Cuts Inappropriate BMA Therapy in Prostate Cancer Study at VA center shows better disease-related bone healthcare Sep 18, 2022
IV Iron Replacements Go Head-to-Head for IBD-Related Anemia Trial confirms higher rate of hypophosphatemia with ferric carboxymaltose Sep 16, 2022
Is Cancer Therapy Also a Lupus Cure? Patients in pilot study show months-long complete remission Sep 15, 2022
Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer But access, cost, and tolerability may favor the latter option, said researcher Sep 14, 2022
Potential Practice-Changer for Refractory Metastatic Colon Cancer Significant survival gain with fruquintinib in patients with heavily pretreated disease Sep 14, 2022
Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer "Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need Sep 14, 2022
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases However, no benefit seen with short-term hormone therapy versus radiotherapy alone Sep 13, 2022
Denosumab Halts Bone Loss From Ovarian Suppression, AIs for Breast Cancer Areal BMD increased when given at the start of maximal estradiol depletion therapy Sep 13, 2022
Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
Triplet in First-Line Kidney Cancer Thwarts Disease Progression Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone Sep 13, 2022
Survival Bump in Unfit NSCLC With First-Line Immunotherapy Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma Studies appear to contradict benefit previously shown with pembrolizumab in this setting Sep 12, 2022
Colorectal Cancer Burden on the Rise in Developed Countries Global study predicts an uptick in incidence and mortality through 2040 Sep 12, 2022
Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
